Overview

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
There are no standardized plasma volume replacement protocols during liver transplantation surgery. The current study is designed to compare efficacy, safety, and costs of perioperative volume replacement with Voluven (Hydroxyethyl starch 130/0.4) and albumin in patients undergoing liver transplantation.
Phase:
Phase 4
Details
Lead Sponsor:
Fresenius Kabi
Treatments:
Hydroxyethyl Starch Derivatives